Abstract
The presence of Galanin and Neuropeptide Y and/or their receptors in several areas of the brain involved in memory, mood, cardiovascular control and food intake indicates that Galanin, and Neuropeptide Y could equilibrate the physiological actions of each other. There is evidence for the existence of interactions between Galanin Receptor and Neuropeptide Y Receptor in the nucleus of the solitarii tract (NTS), hypothalamus and dorsal raphe nucleus probably taking place with the formation of heteromers between Galanin Receptor and Neuropeptide Y Y1 Receptor. The galanin fragment (Gal 1-15) preferring receptors may instead be formed by the GalR1-GalR2 heteromer which in the NTS may interact with Neuropeptide Y Y2 receptors. These receptor heteromers may be one key molecular mechanism for Galanin and its N-terminal fragment (Galanin 1-15) to modulate the function of different types of glia–neuronal networks in the CNS, especially the emotional, metabolic and cardiovascular networks.
Keywords: Galanin, Galanin 1-15, Galanin receptor subtypes, GPCRs, Heteromers, Neuropeptide Y, NPY receptors.
Current Protein & Peptide Science
Title:Galanin Receptor/Neuropeptide Y Receptor Interactions in the Central Nervous System
Volume: 15 Issue: 7
Author(s): Zaida Diaz-Cabiale, Antonio Flores-Burgess, Concepcion Parrado, Manuel Narvaez, Carmelo Millon, Araceli Puigcerver, Rafael Covenas, Kjell Fuxe and Jose A. Narvaez
Affiliation:
Keywords: Galanin, Galanin 1-15, Galanin receptor subtypes, GPCRs, Heteromers, Neuropeptide Y, NPY receptors.
Abstract: The presence of Galanin and Neuropeptide Y and/or their receptors in several areas of the brain involved in memory, mood, cardiovascular control and food intake indicates that Galanin, and Neuropeptide Y could equilibrate the physiological actions of each other. There is evidence for the existence of interactions between Galanin Receptor and Neuropeptide Y Receptor in the nucleus of the solitarii tract (NTS), hypothalamus and dorsal raphe nucleus probably taking place with the formation of heteromers between Galanin Receptor and Neuropeptide Y Y1 Receptor. The galanin fragment (Gal 1-15) preferring receptors may instead be formed by the GalR1-GalR2 heteromer which in the NTS may interact with Neuropeptide Y Y2 receptors. These receptor heteromers may be one key molecular mechanism for Galanin and its N-terminal fragment (Galanin 1-15) to modulate the function of different types of glia–neuronal networks in the CNS, especially the emotional, metabolic and cardiovascular networks.
Export Options
About this article
Cite this article as:
Diaz-Cabiale Zaida, Flores-Burgess Antonio, Parrado Concepcion, Narvaez Manuel, Millon Carmelo, Puigcerver Araceli, Covenas Rafael, Fuxe Kjell and Narvaez A. Jose, Galanin Receptor/Neuropeptide Y Receptor Interactions in the Central Nervous System, Current Protein & Peptide Science 2014; 15 (7) . https://dx.doi.org/10.2174/1389203715666140901111709
DOI https://dx.doi.org/10.2174/1389203715666140901111709 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TH2 Cytokines and Associated Transcription Factors as Therapeutic Targets in Asthma
Current Drug Targets - Inflammation & Allergy Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Androgen Deficiency in Aging Male Questionnaire for the Clinical Detection of Testosterone Deficiency in a Population of Black Sub-Saharan African Men with Type 2 Diabetes Mellitus: Is it a Reliable Tool?
Current Diabetes Reviews Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Nanosuspension as an Efficient Carrier for Improved Ocular Permeation of Voriconazole
Current Pharmaceutical Biotechnology Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Quantification of Shear Stress and Geometric Risk Factors in Carotid Atherosclerosis: Review and Clinical Evidence
Recent Patents on Medical Imaging Communication from Tubular Epithelial Cells to Podocytes through Sirt1 and Nicotinic Acid Metabolism
Current Hypertension Reviews Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection
Infectious Disorders - Drug Targets Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety Assessing Coronary Blood Flow Physiology in the Cardiac Catheterisation Laboratory
Current Cardiology Reviews Effectiveness of Nasal Continuous Positive Airway Pressure (CPAP) Therapy on Cardiovascular Outcomes in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS)
Current Respiratory Medicine Reviews Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease
Current Pharmaceutical Design A New Gene Delivery System Based on Controlled Release Technology
Current Drug Delivery Preparation and Characterization of Diltiazem HCL Loaded Bovine Serum Albumin Nanoparticles by Desolvation Technique
Pharmaceutical Nanotechnology Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology